Vertex Pharmaceuticals Incorporated and Mammoth Biosciences, Inc. announced a new partnership to develop in vivo gene-editing therapies for two genetic diseases using Mammoth?s next-generation CRISPR systems. Driven by its unique protein discovery engine, Mammoth?s CRISPR platform consists of a proprietary toolbox of novel, ultracompact Cas enzymes, including Cas14 and Cas?. The small size of these Mammoth systems, together with further optimized parameters, have the potential to facilitate advanced delivery, which may increase the scope of in vivo gene-editing for genetic diseases.